Chronic kidney disease (CKD) and diabetes often co-exist and, for the majority of cases, the kidney damage and/or reduced kidney function is caused directly by longstanding and poorly controlled diabetes. Improved glycemic control has been suggested to reduce the progression of CKD in type 2 diabetes (T2D) and both glycemic and blood pressure control are key recommendations in international treatment guidelines for CKD in T2D. Yet there remains a major unmet medical need to improve the treatment of CKD in patients with T2D. The purpose of this trial is to demonstrate that semaglutide subcutaneously (s.c.) delays the progression of renal impairment and lowers the risk of renal and cardiovascular mortality in subjects with T2D and CKD.
7-11 phone visits
$50 for in-person visits, $25 for phone visits
Kidneys and Liver